Sucampo Announces Presentation of Results on AMITIZA(R) (lubiprostone) in Opioid-Induced Constipation at Two Upcoming Scientific Conferences
October 11, 2013 06:45 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Oct. 11, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") today announced the presentation of three posters evaluating AMITIZA® (lubiprostone) in...
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at BioCentury(R) NewsMakers in the Biotech Industry 2013 Conference
September 20, 2013 06:45 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Sept. 20, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. ("Sucampo") (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate...
Sucampo to Present Data on AMITIZA(R) (lubiprostone) in Chronic Idiopathic Constipation at Annual Meeting of the Swiss Society of Gastroenterology
September 12, 2013 19:00 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Sept. 12, 2013 (GLOBE NEWSWIRE) -- Sucampo AG ("SAG"), a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo"), announced today that it will present four...